NonExomics is focused on the non-exome regions of the genome and has identified hundreds of potential new drug targets across rare diseases, neuropsychiatric disorders, and cancer.

The parts of our DNA that code for proteins make up around 2% of the human genome and are collectively known as the exome. The exome is the best studied and most well understood part of the genome, and is where the vast majority of known disease-causing variants are found. NonExomics has however identified mutations in nonexomal regions that are strongly associated with poorly diagnosed, poorly treated, or currently deemed incurable diseases.

NonExomics says it has identified – using AI and Proteogenomics – hundreds of new disease-associated biomarkers spanning more than 300 human diseases and has shown that these disease markers are potential drug targets. These nonexomic disease-specific targets include 150 rare diseases, schizophrenia and bipolar neuropsychiatry disorders, and 22 cancers.

Founded in 2021, the company is based on intellectual property licensed from the University of Cambridge. NonExomics’ CEO Dr. Sudhakaran Prabakaran left his University position in 2021 to create the company, which has raised Seed funding so far.

Subscribe for alerts on new companies featured on Startups.Bio